New Jersey Assembly Bill A1322

New Jersey 2024-2025 Regular Session

• Introduced: 1/9/24
• Refer: 1/9/24

Caption

Requires physician to offer to test patient for dihydropyrimidine dehydrogenase deficiency prior to patient undergoing chemotherapy.

Impact

The bill mandates that health insurance plans, including individual and group policies, provide coverage for expenses related to testing for DPD deficiency. This inclusion ensures that patients are not financially burdened when seeking necessary testing before chemotherapy, thereby adhering to a broader ethos of patient-centered care in medical practices. By requiring this coverage, the legislation also aligns healthcare service provisions with patients’ safety needs, enhancing overall care quality during cancer treatments.

Summary

Bill A1322, introduced in the New Jersey Legislature, requires physicians to offer to test patients for dihydropyrimidine dehydrogenase deficiency (DPD deficiency) prior to chemotherapy administration. This deficiency can lead to severe reactions in patients undergoing treatment, hence the testing is aimed at preventing potential adverse health outcomes. The bill highlights the need for proactive measures in healthcare to ensure safe chemotherapy treatments based on individual patient health profiles.

Contention

Discussions surrounding Bill A1322 may involve concerns regarding the implications for healthcare providers and insurers. While proponents argue that requiring testing is essential for preventing severe reactions to chemotherapy, some stakeholders may express concerns about the costs associated with expanding coverage for these tests. Additionally, the balance of responsibilities between physicians and insurers in ensuring compliance with this new requirement could generate debate within the healthcare community.